Lv51
1178 积分 2024-04-18 加入
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
2小时前
已完结
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies
2小时前
已完结
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies
29天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
1个月前
已完结
Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations
1个月前
已完结
Chemical Adaptation in Drug Discovery: The Medicinal Chemistry Journey of Olverembatinib and Limertinib in Overcoming Kinase Drug Resistance
1个月前
已完结
Combination Therapy for EGFR -Mutated Lung Cancer
1个月前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
1个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
1个月前
已完结
The blood–tumour barrier in cancer biology and therapy
1个月前
已完结
皖公网安备34019202002308
